# Fluticasone furoate + Umeclidinium + Vilanterol

## Trelegy Ellipta 92/55/22 mcg Inhalation Powder

| TAH Drug Code      | [ETRE](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ETRE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Asthma， and chronic obstructive pulmonary disease of maintenance.                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Dosing             | Oral inhalation: Dry powder inhaler: One inhalation (fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg) once daily (maximum dose: 1 inhalation/day)                                                                                                                                                                                                                                                                                                                                                                    |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Hypersensitivity to fluticasone， umeclidinium， vilanterol， or any component of the formulation; severe hypersensitivity to milk proteins                                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | 1% to 10%: Headache (4%)， voice disorder (>=1%)， Diarrhea (2%)， dysgeusia (2%)， constipation (>=1%)， oral candidiasis (>=1%)， gastroenteritis (1%)， Urinary tract infection (>=1%)， Influenza (>=1%)， Back pain (4%)， arthralgia (>=1%)， Pneumonia (8%)， bronchitis (>=1%)， pharyngitis (>=1%)， rhinitis (>=1%)， sinusitis (>=1%)， upper respiratory tract infection (>=1%)， cough (1%)， oropharyngeal pain (1%) Frequency not defined:Paradoxical bronchospasm <1%， postmarketing， and/or case reports: Anaphylaxis |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| More Info          | [UpToDate](https://www.uptodate.com/contents/fluticasone-furoate-and-umeclidinium-and-vilanterol-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                       |

